Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
1.050
-0.020 (-1.87%)
Nov 21, 2024, 10:50 AM EST - Market open
Achilles Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 15.97 | 17.01 | 21.12 | 21.97 | 11.1 | 4.7 | |
Research & Development | 55.96 | 58.15 | 50.06 | 42.12 | 22.63 | 9.07 | |
Operating Expenses | 71.93 | 75.16 | 71.18 | 64.1 | 33.73 | 13.78 | |
Operating Income | -71.93 | -75.16 | -71.18 | -64.1 | -33.73 | -13.78 | |
Currency Exchange Gain (Loss) | -1 | -1 | 3.8 | 2.5 | 0.1 | -0.4 | |
Other Non Operating Income (Expenses) | 6.64 | 7.08 | 3.52 | 0.63 | 0.43 | 0.19 | |
EBT Excluding Unusual Items | -66.29 | -69.07 | -63.87 | -60.96 | -33.2 | -13.99 | |
Asset Writedown | -0.1 | -0.1 | -7.2 | -0.1 | - | - | |
Pretax Income | -66.39 | -69.17 | -71.07 | -61.06 | -33.2 | -13.99 | |
Income Tax Expense | 0.49 | 0.49 | 0.11 | 0.04 | 0 | - | |
Net Income | -66.88 | -69.67 | -71.18 | -61.1 | -33.2 | -13.99 | |
Net Income to Common | -66.88 | -69.67 | -71.18 | -61.1 | -33.2 | -13.99 | |
Shares Outstanding (Basic) | 40 | 40 | 39 | 29 | 1 | 1 | |
Shares Outstanding (Diluted) | 40 | 40 | 39 | 29 | 1 | 1 | |
Shares Change (YoY) | 1.45% | 2.13% | 36.59% | 2587.54% | 66.03% | 18.35% | |
EPS (Basic) | -1.66 | -1.74 | -1.82 | -2.13 | -31.14 | -21.79 | |
EPS (Diluted) | -1.66 | -1.74 | -1.82 | -2.13 | -31.14 | -21.79 | |
Free Cash Flow | - | -49.55 | -67.05 | -66.92 | -37.1 | -15.08 | |
Free Cash Flow Per Share | - | -1.24 | -1.71 | -2.34 | -34.80 | -23.49 | |
EBITDA | -67.25 | -70.44 | -67.49 | -60.81 | -32.96 | -13.47 | |
D&A For EBITDA | 4.68 | 4.71 | 3.69 | 3.29 | 0.77 | 0.3 | |
EBIT | -71.93 | -75.16 | -71.18 | -64.1 | -33.73 | -13.78 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.